Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Liver Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A detailed picture of the Metastatic-Liver-Cancer pipeline landscape is provided which includes the disease overview and Metastatic-Liver-Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic-Liver-Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic-Liver-Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Metastatic-Liver-Cancer Emerging Drugs Chapters
This segment of the Metastatic-Liver-Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Metastatic-Liver-Cancer Emerging Drugs
- exoASO STAT6: Codiak BioSciencesexoASOT-STAT6 is an exosome therapeutic candidate engineered using our engExT Platform to overexpress Codiak's novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
- STP 705: SirnaomicsSTP705, is a dual TGF-?1/COX-2 inhibitor. TGF-?1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
- ONCR 177: OncorusONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.
Major Players in Metastatic-Liver-Cancer
There are approx. 20+ key companies which are developing the therapies for Metastatic-Liver-Cancer. The companies which have their Metastatic-Liver-Cancer drug candidates in the most advanced stage, i.e. phase I include, Oncorus.
Phases
This report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Product Type
- Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Metastatic-Liver-Cancer: Pipeline Development Activities
- The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic-Liver-Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
- The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic-Liver-Cancer drugs.
Metastatic-Liver-Cancer Report Insights
- Metastatic-Liver-Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Metastatic-Liver-Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Metastatic-Liver-Cancer drugs?
- How many Metastatic-Liver-Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic-Liver-Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Metastatic-Liver-Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Metastatic-Liver-Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Oncorus
- Sirnaomics
- Codiak BioSciences
- Sorrento Therapeutics
- RemeGen Co.
- Taiho Pharmaceutical Co.
- Amarin Corporation
- Eureka Therapeutics
- Medivir
- AstraZeneca
- Amal Therapeutics
- Boehringer Ingelheim
Key Products
- exoASO STAT6
- STP 705
- ONCR 177
- anti-CEA CAR-T cells
- RC48-ADC
- DNX-2440
- Tas-102
- Ethyl eicosapentaenoic acid
- ECT 204
- ET140203
- MIV-818
- Durvalumab
- STI-1386
- ATP128
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/69m4zb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
